Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 9347.121 | 1.0042 | 1.0058 | 1.4523 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9347.121 | 1.0412 | 1.0564 | 1.4523 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9347.121 | 1.0413 | 1.0566 | 1.4523 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9347.121 | 1.0591 | 1.0807 | 1.4523 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9347.121 | 0.7722 | 0.6739 | 1.4523 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9347.121 | 0.3669 | 0.0028 | 1.4523 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9347.121 | 0.3965 | 0.0579 | 1.4523 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 92 | uM | 9347.121 | 0.2411 | -0.2489 | 1.4523 | |
| HCC1806 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 9376.121 | 1.0170 | 1.0245 | 1.3803 | |
| HCC1806 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 9376.121 | 1.0970 | 1.1387 | 1.3803 | |
| HCC1806 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9376.121 | 1.0460 | 1.0662 | 1.3803 | |
| HCC1806 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9376.121 | 0.9711 | 0.9579 | 1.3803 | |
| HCC1806 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9376.121 | 0.7065 | 0.5550 | 1.3803 | |
| HCC1806 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9376.121 | 0.2167 | -0.3395 | 1.3803 | |
| HCC1806 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9376.121 | 0.0334 | -0.8295 | 1.3803 | |
| HCC1806 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9376.121 | 0.0447 | -0.7895 | 1.3803 | |
| HCC1806 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 92 | uM | 9376.121 | 0.0121 | -0.9185 | 1.3803 | |
| HCC1937 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7833.007 | 1.0252 | 1.0388 | 1.2952 | |
| HCC1937 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7833.007 | 0.7961 | 0.6771 | 1.2952 | |
| HCC1937 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7833.007 | 0.9655 | 0.9466 | 1.2952 | |
| HCC1937 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7833.007 | 1.5550 | 1.8122 | 1.2952 | |
| HCC1937 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7833.007 | 0.7114 | 0.5376 | 1.2952 | |
| HCC1937 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7833.007 | 0.6069 | 0.3601 | 1.2952 | |
| HCC1937 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7833.007 | 0.2486 | -0.3173 | 1.2952 | |
| HCC1937 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7833.007 | 0.3660 | -0.0795 | 1.2952 |